This nonprofit is building the ecosystem to cure epidermolysis bullosa

What It Covers

Martin Steiner, Managing Director of DEBRA Research, explains how the German nonprofit bridges early-stage academic EB research and commercial drug development by funding grants, making equity investments in biotech companies, and building dedicated clinical trial infrastructure for a disease affecting roughly 1-in-20,000 people with a life expectancy of 35–40 years.

Key Questions Answered

• •Nonprofit-as-ecosystem-builder model: Rather than running trials or making drugs, DEBRA Research funds academic grants, takes equity positions as a silent co-investor in biotech companies, builds shared preclinical CRO infrastructure, and funds dedicated clinical trial sites — a multi-pillar approach modeled explicitly on the Cystic Fibrosis Foundation's playbook and replicable for other rare diseases.
• •Dedicated clinical site funding: EB patients require up to three hours daily for bandage changes, making standard health systems inadequate for clinical trial participation. DEBRA Research directly funds specialist physicians and clinical study nurses at expert centers like UMC Groningen to absorb the documentary and personnel burden, enabling sites to attract academic and commercial trial sponsors independently over time.
• •Preclinical CRO partnerships for rare disease access: DEBRA Research established a dedicated academic CRO with Queen Mary University of London to centralize EB-specific assays and patient cell lines, with two to three additional research partners planned. This gives early-stage biotech companies without direct clinic relationships standardized access to scarce patient biosamples and head-to-head compound comparisons.
• •Read-through molecules as near-term therapeutic target: DEBRA Research founded a subsidiary, Read On Therapeutics, currently evaluating 20–25 small-molecule compounds that induce read-through of premature stop codons, restoring functional collagen or keratin production. Compounds are sourced from industry, academia, and other nonprofits, then tested head-to-head in dedicated CROs to identify candidates for first-in-human trials before partnering with pharma.
• •Pharma education as deal-making infrastructure: DEBRA Research spent 18 months educating Leo Pharma on EB through patient panels, landscape briefings, and key opinion leader introductions before Leo acquired Replay, a gene therapy company DEBRA had supported. Organizations targeting pharma partnerships should prioritize speaking commercial language — target product profiles, adverse event frameworks — rather than purely scientific or patient-advocacy framing.